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Endovascular treatment of intractable epistaxis - results of 
a 4-year local audit 
I C Duncan, P A Fourie, C E le Grange, H A van der Walt 
Objective. Transcatheter etnbolisation ts an accepted and 
effective treatment for intractable epistaxis. We analysed our 
success and complication rates and compared these with 
results from other published series. 
Design. Retrospective review. 
Setting. Unitas Interventional Unit, Centurion. 
Methods. Case record review (57 procedures) and telephonic 
interviews (36 traceable respondents). 
Outcome measures. A numerical audit of the success· and 
complication rates for embolisation procedures performed 
during the 4-year period between July 1999 and June 2003. 
Results. A total of 57 endovascular embolisation procedures 
Epistaxis is a common condition affecting an estimated 60% of 
the general population, of whom approximately 6% will seek 
or require medical assistance. 1 Refractory or intractable 
epistaxis is defined as recurrent or persistent bleeding after 
appropriate conservative treatment, or multiple episodes of 
epistaxis over a short period of time, both requiring medical 
attention.' Intractable epistaxis usually arises from the posterior 
or superior parts of the nasal cavity, and is therefore not readily 
controlled by direct pressure, topical cauterisation or anterior 
nasal packing. Arterial ligation has remained the mainstay of 
treatment for intractable posterior epistaxis in many centres.' 
Percutaneous embolisation of the internal maxillary artery in 
patients with nasal haemorrhage was first described by 
Sokoloff et al.4 in 1974. Currently, endovascular embolisation is 
an accepted method of treatment for haemorrhage from the 
nasal cavity or other craniofacial lesions.'·' 
Materials and methods 
A retrospective audit was done of 57 percutaneous 
endovascular embolisation procedures in 51 patients 
performed over the 4-year period between July 1999 and June 
2003 at the Unitas Interventional Unit in Centurion. All 
patients were referred by an otorhinolaryngologist (ENT 
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were performed for intractable epistaxis in 51 patients during; 
this period. Eight patients (15.7%) developed a re•bleed 
between 1 and 33days after etnbolisation,ofwhqn)S~ere t~-< 
embolised, giving a· primary short-term success rate of 86.3% 
and secondary assisted success rate of 94.1%. Thirty-five of36 
respondents {97.2%) reported no further epistaxis duting the 
long-term follOW"up period of 1-47months. The mortality 
rate was 0%, the major morbidity rate was 2% (lstroke) and 
the minor morbidity rate was 25%. 
series. 
S Afr Med J l004; 94:.373-378. 
specialist) after failed conventional treatment, generally 
involving local cauterisation and/or nasal packing. Twelve of 
our patients had also received a blood transfusion before 
embolisation. We reviewed our procedural data notes, with 
further clinical data obtained either from initial referral letters 
or from follow-up notes provided by referring clinicians. 
Long-term telephonic follow-up was obtained for 38 patients 
(respondents). Thirteen patients were untraceable during the 
period of the audit. Of the 38 respondents, 2 had died of 
unrelated causes since the embolisation; telephonic interviews 
were conducted with the remaining 36. The collection of data 
was flawed by incomplete clinical record keeping. The most 
complete data obtained were for the 36 respondents, as much 
of the recorded data could be cross-checked and they could 
also provide missing information in addition to long-term 
follow-up. The long-term follow-up period varied between 1 
and 47 months. 
All embolisation procedures were performed using a Phillips 
V5000 Integris digital monoplane angiography unit. Initial 
diagnostic arteriograms of the internal carotid artery (ICA) and 
external carotid artery (ECA) were obtained on each side. The 
ICA was examined in order to exclude an intracranial 
aneurysm, arteriovenous shunt or frontal tumour as a possible 
cause of the bleeding as well as to identify any arterial supply lfD 
to the nasal cavity from ethmoidal branches of each ophthalmic 
artery (Fig. 1). The ipsilateral internal maxillary artery (IMAX), 
defined as that supplying the nasal cavity from which the 
bleeding was visualised or assumed to arise, was then 
superselectively catheterised using a microcatheter technique 
and embolised in all cases bar one. In the latter case ipsilateral 
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Fig. 1. Selective internal carotid digital subtraction arteriogram 
showing supply to the superior nasal cavity via the ethmoidal 
branches (black arrows) of the ophthalmic artery (white arrow). 
ECA origin was occluded due to atheromatous disease and a 
contralateral IMAX embolisation was performed. Other 
vessels superselectively catheterised and embolised included 
the ipsilateral facial artery (N = 29, 51%), the contralateral 
IMAX (N = 27, 47.4%) the contralateral facial artery (N = 8, 
14%), the ascending pharyngeal artery (N = 1, 1.7%) and the 
accessory meningeal artery (N = 1, 1.7%). The decision to 
embolise arteries other than the ipsilateral IMAX was based on 
the relative contributions of each vessel to the supply of the 
nasal cavity as well as the potential for collateral supply to the 
nasal cavity (Fig. 2). During arteriography the actual site of the 
bleeding usually cannot be identified and often no abnormal 
vessels are seen in the nasal cavities, although in several cases 
a nonspecific generalised nasal mucosal 'blush' due to nasal 
mucosal congestion or arterial tortuosity may be seen (Figs 2b -
2d). The most frequently used embolic agents were 
microparticles in 56 procedures (98.2%) with particle sizes 
ranging from 150 to 700 pm in diameter, usually between 250 
and 500 pm. Other embolic materials used included 
cyanoacrylate (N = 5, 8.8%), platinum microcoils (N = 4, 7%) 
and gelatine sponge (Spongistan) (N = 4, 7%). In all cases 
where no macroscopic cause of the bleeding such as a 
pseudoaneurysm could be identified, and where micro-
particulate embolisation was performed, the desired endpoint 
of embolisation was a significant visible reduction or cessation 
of flow in the target vessel(s) (Fig. 3). Where documented the 
nasal packing was removed in theatre in 56% of cases and 
afterwards in 44% of cases (N = 36). 
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Fig. 2a. Selective external carotid digital subtraction arteriogram 
showing the arterial supply to the nasal cavity via terminal branches 
of the internal maxillary artery (black arrow) and facial artery (white 
arrow). 
Fig. 2b. Selective internal maxillary arteriogram (same case as 
Fig. 2a) showing the typical appearance of the nasal arteries before 
embolisation. No bleeding site is identifiable and the arteries have a 
normal appearance. 
Results 
The male-to-female ratio of our patients was 1.2: 1(28 men and 
23 women), and the mean age was 54.4 years (range: 17- 83 
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Fig. 2c. In some cases a prominent nasal capillary blush may be seen 
in keeping with mucosal congestion. 
Fig. 2d. In others tortuosity of the intranasal arteries may be seen. 
years). Thirty-two cases (63%) were referred between the 
months of May and September. The causes of epistaxis were 
deemed idiopathic in 45 (88.2%), related to trauma in 3 (5.9%), 
post-surgical in 2 (3.9%) and hereditary haemorrhagic 
telangiectasia (HHT) in 1 (2%). Of the 2 cases related to 
previous surgery, 1 had recently undergone removal of an 
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Fig. 3. In the same case as shown in Figs 2a and 2b, a selective 
internal maxillary arteriogram following microparticulate 
embolisation shows very little contrast opacification of the nasal 
branches, indicating a satisfactory angiographical endpoint for 
embolisation. 
osteoma from the sphenoid sinus (with ipsilateral IMAX 
occlusion seen at angiographic examination), while the second 
presented with severe bleeding from a large pseudoaneurysm 
of the distal IMAX following a recent maxillary osteotomy. 
Identifiable risk factors among the respondent group (N = 36) 
included hypertension in 19 (52.8%), smoking in 9 (25%), 
anticoagulation/antiplatelet use in 5 (13.9%) and radiation 
therapy in 1 (2.8%). None of the respondents volunteered any 
history of alcohol or illicit drug abuse. One patient had 
previously undergone radiation therapy for a maxillary 
malignancy deemed inactive at the time of the embolisation. 
One of the non-respondents developed severe epistaxis at 25 
weeks of pregnancy for which no underlying cause was found. 
One 17-year-old girl with a sideroblastic anaemia for which she 
had received multiple blood transfusions over a period of 
several years was referred for a semi-elective procedure, the 
only case in our series not treated on an emergency basis. 
Eight patients (15.7%) developed are-bleed between 1 and 33 
days after the initial embolisation (Table I). Of these, 4 patients 
(7.8%) underwent a second embolisation procedure and 1 
patient with HHT underwent 2 further embolisation 
procedures in our unit and 1 at another centre. Two patients 
(3.9%) underwent additional surgical ligation of the ethmoid 
arteries after which no further bleeding was encountered. One 
of these had a Le Fort II fracture whereas the second had an 
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Table II. Reported success and· complication rates since .1995 (N{%)) · 
Study No. of patients Success rate . Minor complications 
Elahi eta/,/' 57 52(96) None reported 
1995 
Tseng et al./ 114 101 (88) 17 (15) 
1998 
Leppanen et a/.,'5 37 33 (89) 4 (8) 
1999 
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procedural re-bleed; angiographic examination was repeated 
but no further embolisation performed. Therefore, 44 patients 
(86.3%) responded well to a single embolisation procedure. No 
further re-bleeds were noted in the 4 patients who underwent a 
second embolisation procedure, giving a cumulative success 
rate for embolisation alone of 94.1 %. With the exception of the 
HHT patient, none of the 36 respondents reported a late re-
bleed after primary or secondary intervention. There was a 0% 
mortality rate in our series. There was a single major 
complication (2%), namely the development of a right-sided 
cerebral infarction during attempted replacement of a guiding 
catheter in a tortuous carotid artery. Minor complications 
included transient headache in 3 patients (8.3%), transient 
facial pain or paraesthesia in 2 (5.5%) and local groin 
haematoma, pain or prolonged anaesthesia in 4 (11 %). The total 
minor complication rate among the respondent group was 
therefore 25%. 
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Discussion 
Most cases of epistaxis occur in the anterior nasal cavity in the 
region of the anteroinferior septum known as Little's area. 
Underlying this is a confluence of arterial territories, namely 
those of the sphenopalatine artery, the greater palatine artery, 
the facial artery and the anterior and posterior ethmoidal 
arteries. This arterial confluence is known as Kiesselbach's 
plexus.' Anterior epistaxis is usually easily controlled by 
conservative measures including localised pressure, topical 
cauterisation and vasoconstriction, local infiltration with 
antifibrinolytic agents and anterior nasal packing.' Posterior 
(and to a lesser degree superior) epistaxis accounts for about 
5% of all epistaxis cases and can be extremely difficult to 
manage. Posterior nasal packing can be done using gauze or 
balloon catheters. Nasal packing has a reported failure rate of 
26 - 52% and a complication rate of 69%. These complications 
include nasal trauma, vasovagal response, aspiration, 
displacement of the packing, persistent bleeding, infection, 
toxic shock syndrome and hypoxia.'· 10 Surgical approaches 
include transantralligation of the distal IMAX and ligation of 
the ethmoid arteries for superior epistaxis.3 More recently, 
endoscopic cauterisation and arterial ligation techniques have 
been described although these are technically more 
demanding.11 The endovascular management of epistaxis has 
become an established alternative to surgical ligation. In a 
comparison of efficacy between transantralligation and 
embolisation in intractable epistaxis, Strong et al." reported 
success rates from the literature of 85% and 90% and average 
complication rates of 28% and 27% respectively for ligation and 
embolisation, with success rates of 89% and 94% respectively 
from their own series. Cullen and Tami'3 showed a failure rate 
of 21% for embolisation versus 27% for ligation (with or 
without ethmoid ligation) and an overall complication rate of 
16% for embolisation and 18% for IMAX ligation. In their 
review of the literature, which expanded upon that by Strong et 
al., they reported a slightly higher failure rate for embolisation 
(20%) than for IMAX ligation (18%) but a significantly higher 
complication rate for IMAX ligation (26%) than for 
embolisation (14%). No difference in major complication rates 
(5% v. 4%) was noted between the two methods. 
The goal of embolisation is simply to reduce the arterial 
pressure head to the affected region without causing any 
ischaemic damage to the nasal soft tissues.7 This in turn allows 
the body to heal itself. The posterior nasal cavity is supplied 
mainly via the sphenopalatine artery and greater palatine 
artery, both being terminal branches of the IMAX. This means 
that the management of posterior epistaxis largely hinges 
around control of the sphenopalatine artery. This also explains 
the equally high rate of success of ipsilateral IMAX 
embolisation alone. However, there is still a failure rate of 10 -
15% for both embolisation and IMAX/ sphenopalatine ligation. 
Furthermore, as shown by Vitek,' the technical success rate of 
embolisation increases significantly when additional 
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embolisation of the ipsilateral facial and contralateral IMAX 
arteries is performed as well. This attests to the importance of 
collateral vessels in the facial region with collateral blood 
supply to the posterior nasal cavity, which probably accounts 
for a significant percentage of failed IMAX ligation and 
embolisation procedures.14 The advantage of arteriography is 
that it can often identify these collateral sources allowing them 
to be treated simultaneously as well. Over 50% of our cases 
involved multiple vessel embolisation. Collateral supply to the 
nasal cavity leading to recurrent haemorrhage occurred in 4 of 
our cases (Table I). Collateral supply via the ethmoid arteries 
led to secondary surgical intervention in 2 cases. Another 
potential complication related to collateral circulation is the 
presence of intracranial-extracranial arterial anastomoses 
where inadvertent embolisation through these pathways can 
lead to ophthalmologic or neurological complications.' It is 
therefore vital to identify these communications during the 
initial angiographic investigation. Two of our cases with a re-
bleed following initial embolisation of the ipsilateral IMAX 
underwent a second procedure involving a repeat 
microparticulate embolisation of the same vessel, with good 
outcome. Inadequate embolisation, as with incomplete IMAX 
ligation, can therefore lead to recurrent bleeding. One patient 
who had a re-bleed 2 days after embolisation underwent a 
repeat arteriogram which showed adequate occlusion of the 
ipsilateral distal IMAX branches. No significant collateral 
vessels were identified and so no further embolisation was 
performed. No further bleeding was experienced thereafter. 
False re-bleeds following embolisation may occasionally be 
encountered and may be due to retained blood in and around 
the nasal packing or blood draining from the paranasal sinuses. 
We used microcatheter techniques in all cases but 1. 
Although leading to increased expense and procedural 
duration and complexity, the use of microcatheters has been 
reported in reducing the number of local cranial complications, 
although to date this has not been proved in any randomised 
study.15•16 In Table II we reviewed 4 studies conducted in or 
after 1995, where the routine use of microcatheter techniques 
was reported. Here we calculated the cumulative success rate 
of 90.2% and overall complication rate of 13.4% (11.4% minor 
and 2% major) with microcatheter usage. Therefore although 
the use of microcatheter techniques does not improve the 
overall success rate, there is a tendency towards a lesser 
complication rate. This factor should be weighed up against the 
additional procedural costs involved per case. Using 
microcatheters we have noted a lesser frequency of arterial 
vasospasm that can also prolong and complicate a procedure. liiJ 
One problem that is apparent in the series reported to date is 
inconsistency in the reporting of minor and major 
complications and hence variation in the reported figures. 
Other factors such as improvements in catheter and guidewire 
design and increased operator experience have also probably 
contributed to the reduction in complication rates in more 
recent times. 
- - ~- ---------------------------
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Other complications related to embolisation for epistaxis that 
have been reported in other local institutions include ischaemic 
necrosis of the upper lip (facial arterial embolisation), unilateral 
trismus (related to deep temporal arterial occlusion) and 
ischaemic sialadenitis (facial artery embolisation). Further 
complications described in the literature include facial nerve 
paralysis, tongue necrosis, tonsillar ulceration, facial atrophy 
and transient submandibular gland swelling. Other potential 
complications can be related to the femoral access (pain, 
bruising, pseudoaneurysm or arteriovenous fistula) or to the 
use of contrast media (allergic reaction, renal failure). Our 
single major complication was a stroke related to attempted 
replacement of a guiding catheter in an extremely tortuous 
carotid artery. 
One advantage of endovascular treatment is that it can be 
performed under local anaesthesia with sedation if required. 
Although only 38.6% of our cases were performed under 
general anaesthesia, our accumulated experience has now led 
us to utilise general anaesthesia routinely for 2 reasons. Firstly, 
these patients are generally uncomfortable, with nasal packing 
in situ and occasionally active bleeding during the procedure as 
well. Prolonged immobilisation on the angiography table may 
be required during difficult cases. This results in further 
patient discomfort and reduced co-operation, with movement 
(voluntary and involuntary) rendering the use of electronic 
vascular roadmapping useless, further prolonging the 
procedure and adding to the risk of complications or an 
incomplete or inadequate procedure. Secondly, we now insist 
on full airway protection by means of a cuffed endotracheal 
tube before commencing any embolisation procedure in the 
head and neck region, where active bleeding is an issue. 
Regardless of whether or not a general anaesthetic is 
administered, an anaesthetist is always present for patient 
monitoring and administration of analgesic or sedative drugs 
as required. 
One subgroup of patients who develop recurrent epistaxis 
are those with HHT (Osler-Weber-Rendu disease), a genetic 
multisystemic angiodysplasia. These patients develop fragile 
nasal mucosal telangiectasias and are prone to repeated and 
intractable epistaxis in more than 90% of cases. Embolisation is 
not a definitive treatment for epistaxis in these patients but can 
control an acute bleeding episode. Because of the known 
propensity for epistaxis to recur in these patients, Elden et a/.16 
found that their long-term success rate for embolisation 
increased from 82% to 90% once the HHT patients in their 
series were excluded. There is still no definitive treatment 
liiJ available for the nasal manifestations of HHT. We have 
successfully palliated our patient for more than 18 months 
using intramucosal injections of bleomycin (unpublished data). 
Although embolisation is a good alternative to surgical 
IMAX ligation (or related procedures), interventional expertise 
is only available in the major centres in South Africa. Fifteen 
patients were referred from within the Pretoria area, with 36 
others being transferred from other centres, generally from 
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within a 150 km radius of our unit. In their study of the 
attitudes of practising otorhinolaryngologists in Ohio, Cullen 
and Tami'' found that before publication of their article in 1998, 
only 16% had referred patients for embolisation, of whom 
three-quarters were from urban practices and the rest from 
rural areas. Also, more urban than rural hospitals had 
embolisation facilities. This finding is mirrored and 
undoubtedly amplified in South Africa. In their comparison of 
the cost of IMAX ligation versus that of embolisation, Strong et 
al.12 found the average cost per case in 1994 for antral ligation 
to be US$5 941 versus US$6 783 for embolisation. Cullen and 
Tami'' calculated the average costs in their institution in 1998 to 
be US$6 184.55 for IMAX ligation and US$4 544.85 for 
embolisation. No comparative figures are available locally. 
In conclusion, intractable epistaxis is a debilitating condition 
and treatment can be extremely difficult. Percutaneous 
transcatheter embolisation of the nasal arteries is an accepted 
alternative to surgical intervention, with comparable major and 
minor complication rates, success rates and overall costs. 
Most cases will respond well to a single embolisation 
procedure, with approximately 10% failing to respond owing 
to factors such as collateral arterial supply, HHT, etc. These 
procedures should only be performed by suitably experienced 
interventional radiologists either under general anaesthesia or 
at least with full monitoring and anaesthetic backing. 
Thanks to Lizl Geldenhuis for her assistance with preparation of 
this manuscript. 
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